Electronic Supplementary Material (ESI) for RSC Advances.
This journal is © The Royal Society of Chemistry 2024

Supporting Information

Morpholine modified Ru-based agents with multiple antibacterial mechanisms as metalloantibiotic candidates against *Staphylococcus aureus* infection

Shijie Lin[a§], Yun Song[b§], Yajuan Sun[b§], Wenjing Lin[b], Guangying Yu[b], Xiangwen Liao[b], Qiang Yang[c*]

[a] Department of Pharmacy, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, 570311, China

[b] Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang, 330013, China

[c] Department of Clinical Pharmacy, Hainan Cancer Hospital, Haikou, 570100, China

§ These authors contribute equally to this work

* Correspondence author:

Qiang Yang, E-mail: 18789551643@163.com



Figure S1. The ^{1}H NMR of **MPLP** ligand



Figure S2. The ^{13}C NMR spectrum of the **MPLP**.



Figure S3. The HMRS of ligand **MPLP**.



Figure S4. The ^{1}H NMR of **Ru(II)-1**.



Figure S5. The ^{13}C NMR spectrum of the **Ru(II)-1**.



Figure S6. The IR spectrum of the **Ru(II)-1**.



Figure S7. The HMRS of ligand **Ru(II)-1**.



Figure S8. The HPLC of **Ru(II)-1**.



Figure S9. The ^{1}H NMR of **Ru(II)-2**.



Figure S10. The ^{13}C NMR spectrum of the **Ru(II)-2**.



Figure S11. The IR spectrum of the **Ru(II)-2**.



Figure S12. The HMRS of ligand **Ru(II)-2**.



Figure S13. The HPLC of **Ru(II)-2**.



Figure S14. The ^{1}H NMR of **Ru(II)-3**.



Figure S15. The ^{13}C NMR spectrum of the **Ru(II)-3**.



Figure S16. The IR spectrum of the **Ru(II)-3**



Figure S17. The HMRS of ligand **Ru(II)-3**.



Figure S18. The HPLC of **Ru(II)-3**.



Figure S19. The ^{1}H NMR of **Ru(II)-4**.



Figure S20. The ^{13}C NMR spectrum of the **Ru(II)-4**.



Figure S21. The IR spectrum of the **Ru(II)-4**



Figure S22. The HMRS of ligand **Ru(II)-4**.



Figure S23. The HPLC of **Ru(II)-4**.



Figure S24. The ^{1}H NMR of **Ru(II)-5**.



Figure S25. The ^{13}C NMR spectrum of the **Ru(II)-5**.



Figure S26. The IR spectrum of the **Ru(II)-5**



Figure S27. The HMRS of ligand **Ru(II)-5**.



Figure S28. The HPLC of **Ru(II)-5**.



Figure S29. The images of the hemolytic effect of **Ru(II)-3** on rabbit blood cell.

Table S1. Minimum inhibitory concentration (MIC) values of **Ru(II)-3** against drug-resistant *S. aureus* (MRSA) isolated from the clinic.

Compound	MIC μg/mL
Ru(II)-3	0.2
Clindamycin	Resistance
Penicillin G	Resistance